<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">PAR</journal-id><journal-title-group><journal-title>Proceedings of Anticancer Research</journal-title></journal-title-group><issn>2208-3545</issn><eissn>2208-3553</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/par.v6i1.2840</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Improvement of Clinical Symptoms and Gut Microbiome After Fecal Microbiota Transplantation: A Case Study of a 106-Year-Old Man with MODS</title><url>https://artdesignp.com/journal/PAR/6/1/10.26689/par.v6i1.2840</url><author>FangJingyun,YinJiayu,LiuQinghong,YangXiangyi,HeXuesong,WangShengzhou,FanMin,AlnaggarMohammed,WangJingsu,DengZhaoqun,LiuYuanfei</author><pub-date pub-type="publication-year"><year>2022</year></pub-date><volume>6</volume><issue>1</issue><history><date date-type="pub"><published-time>2022-01-19</published-time></date></history><abstract>Fecal microbiota transplantation (FMT) has been used in a wide variety of diseases. Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infections; thus, FMT is a potential therapeutic target against multiple organ dysfunction syndrome (MODS). A 106-year-old male patient was initially diagnosed with cerebral infarction and pulmonary infection. During the course of hospitalization, the patient developed MODS. The patient received a single nasogastric infusion of sterile-filtered, pathogen-free feces from a healthy donor. Fecal samples were collected every two days post-infusion to monitor changes in the microbiota composition in response to treatment. After FMT, MODS and severe diarrhea were alleviated; the patient’s fecal microbiome diversity resembled that of the healthy donor’s fecal microbiome; moreover, his clinical symptoms improved remarkably with the changes in fecal microbiome. Additionally, no observable side effects were noted during FMT treatment. These findings warrant further investigation of FMT as a putative new therapy for treating microbiota-related diseases, such as MODS.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Wang J-W, Kuo C-H, Kuo F-C, et al., 2019, Fecal Microbiota Transplantation: Review and Update. J Formos Med Assoc, 118 Suppl 1: S23-S31.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Vindigni SM, Surawicz CM, 2017, Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, 46(1): 171-185.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Bibbò S, Ianiro G, Gasbarrini A, et al., 2017, Fecal Microbiota Transplantation: Past, Present and Future Perspectives. Minerva Gastroenterol Dietol, 63(4): 420-430.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Laffin M, Millan B, Madsen KL, 2017, Fecal Microbial Transplantation as a Therapeutic Option in Patients Colonized with Antibiotic Resistant Organisms. Gut Microbes, 8(3): 221-224.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Zhang F, Cui B, He X, et al., 2018, Microbiota Transplantation: Concept, Methodology and Strategy for Its Modernization. Protein &amp; Cell, 9(5): 462-473.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>van Nood E, Vrieze A, Nieuwdorp M, et al., 2013, Duodenal Infusion of Donor Feces for Recurrent Clostridium Difficile. The New England Journal of Medicine, 368(5): 407-415.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Althani AA, Marei HE, Hamdi WS, et al., 2016, Human Microbiome and Its Association with Health and Diseases. Journal of Cellular Physiology, 231(8): 1688-1694.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Ramírez M, 2013, Multiple Organ Dysfunction Syndrome. Current Problems in Pediatric and Adolescent Health Care, 43(10): 273-277.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Rosenthal MD, Moore FA, 2016, Persistent Inflammation, Immunosuppression, and Catabolism: Evolution of Multiple Organ Dysfunction. Surgical Infections, 17(2): 167-172.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Wei Y, Yang J, Wang J, et al., 2016, Successful Treatment with Fecal Microbiota Transplantation in Patients with Multiple Organ Dysfunction Syndrome and Diarrhea Following Severe Sepsis. Crit Care, 20(1): 332.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Caporaso JG, Kuczynski J, Stombaugh J, et al., 2010, QIIME Allows Analysis of High-Throughput Community Sequencing Data. Nature Methods, 7(5): 335-336.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Quast C, Pruesse E, Yilmaz P, et al., 2013, The SILVA Ribosomal RNA Gene Database Project: Improved Data Processing and Web-Based Tools. Nucleic Acids Research, 41(Database issue): D590-596.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Sender R, Fuchs S, Milo R, 2016, Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell, 164(3): 337-340.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Kelly TN, Bazzano LA, Ajami NJ, et al., 2016, Gut Microbiome Associates with Lifetime Cardiovascular Disease Risk Profile Among Bogalusa Heart Study Participants. Circulation Research, 119(8): 956-964.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Klingensmith NJ, Coopersmith CM, 2016, Fecal Microbiota Transplantation for Multiple Organ Dysfunction Syndrome. Critical Care, 20(1): 398.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><p>Krajicek E, Bohm M, Sagi S, et al., 2019, Fulminant Clostridium Difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient with Critical Neutropenia. ACG Case Reports Journal, 6(8): e00198.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
